Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Eriocalyxin B Inhibits Nuclear Factor-κB Activation by Interfering with the Binding of Both p65 and p50 to the Response Element in a Noncompetitive Manner

Chung-Hang Leung, Susan P. Grill, Wing Lam, Wenli Gao, Han-Dong Sun and Yung-Chi Cheng
Molecular Pharmacology December 2006, 70 (6) 1946-1955; DOI: https://doi.org/10.1124/mol.106.028480
Chung-Hang Leung
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Susan P. Grill
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wing Lam
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wenli Gao
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Han-Dong Sun
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yung-Chi Cheng
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Nuclear factor-κB (NF-κB) has been recognized to play a critical role in cell survival and inflammatory processes. It has become a target for intense drug development for the treatment of cancer, inflammatory, and autoimmune diseases. Here, we describe a potent NF-κB inhibitor, eriocalyxin B (Eri-B), an ent-kauranoid isolated from Isodon eriocalyx, an anti-inflammatory remedy. The presence of two α,β-unsaturated ketones give this compound the uniqueness among the ent-kauranoids tested. Eri-B inhibited the NF-κB transcriptional activity but not that of cAMP response element-binding protein. It suppressed the transcription of NF-κB downstream gene products including cyclooxygenase-2 and inducible nitric-oxide synthase induced by tumor necrosis factor-α or lipopolysaccharide in macrophages and hepatocarcinoma cells. Chromatin immunoprecipitation assay indicated that Eri-B selectively blocked the binding between NF-κB and the response elements in vivo without affecting the nuclear translocation of the transcription factor. Down-regulation of the endogenous p65 protein sensitized the cells toward the action of the compound. Furthermore, in vitro binding assays suggested that Eri-B reversibly interfered with the binding of p65 and p50 subunits to the DNA in a noncompetitive manner. In summary, this study reveals the novel action of a potent NF-κB inhibitor that could be potentially used for the treatment of a variety of NF-κB-associated diseases. Modification of the structure of this class of compounds becomes the key to the control of the behavior of the compound against different cellular signaling pathways.

Footnotes

  • Y.-C.C. is a Fellow of the National Foundation for Cancer Research. Part of this work was supported by the Natural Science Foundation of Yunnan Province (2004C0008Z).

  • ABBREVIATIONS: NF-κB, nuclear factor-κB; TNF-α, tumor necrosis factor-α; LPS, lipopolysaccharide; PMA, phorbol-12-myristate-13-acetate; FSK, forskolin; IKK, IκB kinase; PCR, polymerase chain reaction; COX-2, cyclooxygenase-2; iNOS, inducible nitric-oxide synthase; ChIP, chromatin immunoprecipitation; EMSA, electrophoretic mobility shift assay; CRE, cAMP response element; MAPK, mitogen-activated protein kinase; ERK1/2, extracellular signal-regulated kinase 1 and 2; Dox, doxycycline; PKC, protein kinase C; NP-40, Nonidet P-40; PAGE, polyacrylamide gel electrophoresis; shRNA, short hairpin RNA; Eri-B, eriocalyxin B; DTT, dithiothreitol; CREB, cAMP response element-binding protein; PS-341, bortezomib.

    • Received June 30, 2006.
    • Accepted August 29, 2006.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology: 70 (6)
Molecular Pharmacology
Vol. 70, Issue 6
1 Dec 2006
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Eriocalyxin B Inhibits Nuclear Factor-κB Activation by Interfering with the Binding of Both p65 and p50 to the Response Element in a Noncompetitive Manner
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Eriocalyxin B Inhibits Nuclear Factor-κB Activation by Interfering with the Binding of Both p65 and p50 to the Response Element in a Noncompetitive Manner

Chung-Hang Leung, Susan P. Grill, Wing Lam, Wenli Gao, Han-Dong Sun and Yung-Chi Cheng
Molecular Pharmacology December 1, 2006, 70 (6) 1946-1955; DOI: https://doi.org/10.1124/mol.106.028480

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Eriocalyxin B Inhibits Nuclear Factor-κB Activation by Interfering with the Binding of Both p65 and p50 to the Response Element in a Noncompetitive Manner

Chung-Hang Leung, Susan P. Grill, Wing Lam, Wenli Gao, Han-Dong Sun and Yung-Chi Cheng
Molecular Pharmacology December 1, 2006, 70 (6) 1946-1955; DOI: https://doi.org/10.1124/mol.106.028480
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Upacicalcet binds to the amino acid binding site of CaSR
  • Characterization of GRD and LCCH3 from Human Louse
  • Resveratrol Acts as an NR4A1 Antagonist in Lung Cancer
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics